BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23741347)

  • 21. A rare connection: fasciculoventricular pathway in PRKAG2 disease.
    Govindan M; Ward D; Behr E
    J Cardiovasc Electrophysiol; 2010 Mar; 21(3):329-32. PubMed ID: 19732236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.
    Ramratnam M; Sharma RK; D'Auria S; Lee SJ; Wang D; Huang XY; Ahmad F
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25092788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRKAG2 mutations presenting in infancy.
    Torok RD; Austin SL; Phornphutkul C; Rotondo KM; Bali D; Tatum GH; Wechsler SB; Buckley AF; Kishnani PS
    J Inherit Metab Dis; 2017 Nov; 40(6):823-830. PubMed ID: 28801758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controversial molecular functions of CBS versus non-CBS domain variants of PRKAG2 in arrhythmia and cardiomyopathy: A case report and literature review.
    Gong X; Yu P; Wu T; He Y; Zhou K; Hua Y; Lin S; Wang T; Huang H; Li Y
    Mol Genet Genomic Med; 2022 Jul; 10(7):e1962. PubMed ID: 35588295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of a PRKAG2 cardiac syndrome disease model and mechanism study using human induced pluripotent stem cells.
    Zhan Y; Sun X; Li B; Cai H; Xu C; Liang Q; Lu C; Qian R; Chen S; Yin L; Sheng W; Huang G; Sun A; Ge J; Sun N
    J Mol Cell Cardiol; 2018 Apr; 117():49-61. PubMed ID: 29452156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities.
    Ben Jehuda R; Eisen B; Shemer Y; Mekies LN; Szantai A; Reiter I; Cui H; Guan K; Haron-Khun S; Freimark D; Sperling SR; Gherghiceanu M; Arad M; Binah O
    Heart Rhythm; 2018 Feb; 15(2):267-276. PubMed ID: 28917552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation.
    Kelly BP; Russell MW; Hennessy JR; Ensing GJ
    Pediatr Cardiol; 2009 Nov; 30(8):1176-9. PubMed ID: 19787389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial Atrial Enlargement, Conduction Disorder and Symmetric Cardiac Hypertrophy Are Early Signs of PRKAG2 R302Q.
    Hu J; Tang B; Wang J; Huang K; Wang Y; Lu S; Gowreesunkur HB; Wang Y; Wu D; Mayala HA; Wang ZH
    Curr Med Sci; 2020 Jun; 40(3):486-492. PubMed ID: 32681253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac manifestations of PRKAG2 mutation.
    Banankhah P; Fishbein GA; Dota A; Ardehali R
    BMC Med Genet; 2018 Jan; 19(1):1. PubMed ID: 29298659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.
    Xie C; Zhang YP; Song L; Luo J; Qi W; Hu J; Lu D; Yang Z; Zhang J; Xiao J; Zhou B; Du JL; Jing N; Liu Y; Wang Y; Li BL; Song BL; Yan Y
    Cell Res; 2016 Oct; 26(10):1099-1111. PubMed ID: 27573176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations.
    Thevenon J; Laurent G; Ader F; Laforêt P; Klug D; Duva Pentiah A; Gouya L; Maurage CA; Kacet S; Eicher JC; Albuisson J; Desnos M; Bieth E; Duboc D; Martin L; Réant P; Picard F; Bonithon-Kopp C; Gautier E; Binquet C; Thauvin-Robinet C; Faivre L; Bouvagnet P; Charron P; Richard P
    Europace; 2017 Apr; 19(4):651-659. PubMed ID: 28431061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel mutations including a double mutation in patients with inherited cardiomyopathy by a targeted sequencing approach using the Ion Torrent PGM system.
    Zhao Y; Cao H; Song Y; Feng Y; Ding X; Pang M; Zhang Y; Zhang H; Ding J; Xia X
    Int J Mol Med; 2016 Jun; 37(6):1511-20. PubMed ID: 27082122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of cardiac hypertrophic signaling pathways in a transgenic mouse with the human PRKAG2 Thr400Asn mutation.
    Banerjee SK; McGaffin KR; Huang XN; Ahmad F
    Biochim Biophys Acta; 2010 Feb; 1802(2):284-91. PubMed ID: 20005292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history.
    Murphy RT; Mogensen J; McGarry K; Bahl A; Evans A; Osman E; Syrris P; Gorman G; Farrell M; Holton JL; Hanna MG; Hughes S; Elliott PM; Macrae CA; McKenna WJ
    J Am Coll Cardiol; 2005 Mar; 45(6):922-30. PubMed ID: 15766830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Same genotype and different phenotypes in a family with PRKAG2 gene mutation].
    Hong K; Oliva A; Cheng XS; Brugada P; Brugada J; Sternick EB; Brugada R
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jun; 35(6):552-4. PubMed ID: 17711718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac hypertrophy, accessory pathway, and conduction system disease in an adolescent: the PRKAG2 cardiac syndrome.
    Fabris E; Brun F; Porto AG; Losurdo P; Vitali Serdoz L; Zecchin M; Severini GM; Mestroni L; Di Chiara A; Sinagra G
    J Am Coll Cardiol; 2013 Aug; 62(9):e17. PubMed ID: 23810891
    [No Abstract]   [Full Text] [Related]  

  • 37. Molecular genetic analysis of PRKAG2 in sporadic Wolff-Parkinson-White syndrome.
    Vaughan CJ; Hom Y; Okin DA; McDermott DA; Lerman BB; Basson CT
    J Cardiovasc Electrophysiol; 2003 Mar; 14(3):263-8. PubMed ID: 12716108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis.
    Laforêt P; Richard P; Said MA; Romero NB; Lacene E; Leroy JP; Baussan C; Hogrel JY; Lavergne T; Wahbi K; Hainque B; Duboc D
    Neuromuscul Disord; 2006 Mar; 16(3):178-82. PubMed ID: 16487706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase.
    Akman HO; Sampayo JN; Ross FA; Scott JW; Wilson G; Benson L; Bruno C; Shanske S; Hardie DG; Dimauro S
    Pediatr Res; 2007 Oct; 62(4):499-504. PubMed ID: 17667862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic expression and clinical outcomes in a South Asian PRKAG2 cardiomyopathy cohort.
    Ahamed H; Balegadde AV; Menon S; Menon R; Ramachandran A; Mathew N; Natarajan KU; Nair IR; Kannan R; Shankar M; Mathew OK; Nguyen TT; Gupta R; Stawiski EW; Ramprasad VL; Seshagiri S; Phalke S
    Sci Rep; 2020 Nov; 10(1):20610. PubMed ID: 33244021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.